On the contrary, ~97% of ovarian cancer patients with high-grade serous (HGS) carcinoma have been tested positive for defective p53 pathways in large scale genomic analyses [102,103], highlighting the potential of OAd-based therapies targeting this pathway in ovarian cancer. Here, TP53 is linked to ovarian cancer.